Evoke Pharma Statistics
Total Valuation
Evoke Pharma has a market cap or net worth of $6.66 million. The enterprise value is -$657,538.
Important Dates
The last earnings date was Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evoke Pharma has 2.07 million shares outstanding.
| Current Share Class | 1.49M |
| Shares Outstanding | 2.07M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.92% |
| Owned by Institutions (%) | 3.92% |
| Float | 1.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.59 |
| Forward PS | 0.94 |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.88.
| Current Ratio | 1.55 |
| Quick Ratio | 1.45 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.01 |
Financial Efficiency
Return on equity (ROE) is -108.77% and return on invested capital (ROIC) is -32.11%.
| Return on Equity (ROE) | -108.77% |
| Return on Assets (ROA) | -21.70% |
| Return on Invested Capital (ROIC) | -32.11% |
| Return on Capital Employed (ROCE) | -84.47% |
| Revenue Per Employee | $3.86M |
| Profits Per Employee | -$1.69M |
| Employee Count | 3 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.67% in the last 52 weeks. The beta is 0.15, so Evoke Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -41.67% |
| 50-Day Moving Average | 2.87 |
| 200-Day Moving Average | 4.34 |
| Relative Strength Index (RSI) | 64.01 |
| Average Volume (20 Days) | 13,537 |
Short Selling Information
The latest short interest is 24,685, so 1.19% of the outstanding shares have been sold short.
| Short Interest | 24,685 |
| Short Previous Month | 25,894 |
| Short % of Shares Out | 1.19% |
| Short % of Float | 1.95% |
| Short Ratio (days to cover) | 1.38 |
Income Statement
In the last 12 months, Evoke Pharma had revenue of $11.59 million and -$5.08 million in losses.
| Revenue | 11.59M |
| Gross Profit | 11.29M |
| Operating Income | -5.00M |
| Pretax Income | -7.13M |
| Net Income | -5.08M |
| EBITDA | n/a |
| EBIT | -5.00M |
| Earnings Per Share (EPS) | n/a |
Full Income StatementBalance Sheet
The company has $12.62 million in cash and $5.14 million in debt, giving a net cash position of $7.48 million or $3.61 per share.
| Cash & Cash Equivalents | 12.62M |
| Total Debt | 5.14M |
| Net Cash | 7.48M |
| Net Cash Per Share | $3.61 |
| Equity (Book Value) | 5.84M |
| Book Value Per Share | n/a |
| Working Capital | 5.78M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.88M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 97.36%, with operating and profit margins of -43.17% and -43.80%.
| Gross Margin | 97.36% |
| Operating Margin | -43.17% |
| Pretax Margin | -43.80% |
| Profit Margin | -43.80% |
| EBITDA Margin | n/a |
| EBIT Margin | -43.17% |
| FCF Margin | n/a |